Existing systematic reviews of cancer detection have focused on isolated tumour markers in relation to single cancers, such as serum HER2 for breast cancer [51]; IMP-1, CEA, and CA19-9 for pancreatic cancer [52]; and CEA, CA-125, PSA, and others for colorectal cancer [53]. This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.